NCT07176507 MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Heart Disease
| NCT ID | NCT07176507 |
| Status | Recruiting |
| Phase | — |
| Sponsor | French Cardiology Society |
| Condition | Valvular Heart Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2028-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-10-30 with a primary completion date of 2028-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres. In order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease. The multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * The patient has been informed of the study and has not refused to participate. * An echocardiographic diagnosis of MMVD is defined as having at least two moderate to severe valvulopathies, as assessed by a cardiologist using transthoracic echocardiography (TTE), on one or more valves. This is in line with the recommendations of the ESC, the ASE, and expert opinion. Exclusion Criteria: * History of valve surgery or percutaneous valve intervention involving the valve in question. * A history of infective endocarditis, whether treated surgically or not, confirmed according to the modified Duke criteria. * Acute infective endocarditis at the time of evaluation for inclusion, confirmed according to the modified Duke criteria. * Complex congenital heart disease. * Patients who are already included in the European EACVI-MMVD study. * Pregnant women * Patients not affiliated to social security * Patients who are minors * Patients under guardianship, curatorship or judicial supervision * Patients who refuse to participate in this register.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07176507 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Valvular Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07176507 currently recruiting?
Yes, NCT07176507 is actively recruiting participants. Contact the research team at multivalve@sfcardio.fr for enrollment information.
Where is the NCT07176507 trial being conducted?
This trial is being conducted at Lille, France, Paris, France.
Who is sponsoring the NCT07176507 clinical trial?
NCT07176507 is sponsored by French Cardiology Society. The trial plans to enroll 1,000 participants.